Navigation Links
MAP Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
Date:11/11/2009

MOUNTAIN VIEW, Calif., Nov. 11 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the company will present at the Lazard Capital Markets 6th Annual Healthcare Conference on Wednesday, November 18, 2009 at 9:00 a.m. ET in New York City.

A live webcast of the presentation will be available on the Investor Relations section of MAP Pharmaceuticals' website at http://www.mappharma.com. A replay will also be available within 24 hours for seven days following the presentation.

About MAP Pharmaceuticals

MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for patients suffering from conditions that are not adequately treated by currently available medicines. The company is developing LEVADEX(TM) orally inhaled therapy for the potential treatment of migraine and has reported positive results from the efficacy portion of the first Phase 3 trial of LEVADEX. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

Contact: Lisa Borland 650-386-3122

SOURCE MAP Pharmaceuticals, Inc.


'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... NeuroRx, a clinical stage biopharma company developing the first oral ... granted Fast Track status by the US Food and Drug ... by NRX-101 (D-cycloserine + lurasidone). The company will shortly begin ... targeting patients who are admitted to Emergency Departments with ASIB ... ...
(Date:9/5/2017)... Sept. 5, 2017 Sapheneia and Scannerside received ... Scannerside DoseCheck is a third-party Vendor neutral CT product ... and allows compliance with current MITA standards. ... 29 DoseCheck solution is specifically designed to provide CT ... potential radiation doses over a predefined threshold. Scannerside Dose ...
(Date:9/5/2017)... WAYNE, N.J. , Sept. 5, 2017 /PRNewswire/ ... technology, has created a vibrant charitable donation program ... funds and support congenital heart defect research by ... healthcare providers and the general public are encouraged ... and submit the completed artwork to the ...
Breaking Medicine Technology:
(Date:9/21/2017)... ... September 21, 2017 , ... Innovatum will demonstrate capabilities of ... Healthcare Conference 2017 in Chicago, IL on October 17-19, 2017. This unique development ... improving patient safety. , Microscan , a global technology leader in ...
(Date:9/21/2017)... ... ... FlipBelt, the fitness brand that specializes in problem solving fitness accessories, has ... the launch of their FlipBelt Crops. , The new fitness bottoms feature an integrated ... at the gym, on the trail, or on-the-go. , “We always thought the FlipBelt ...
(Date:9/20/2017)... ... 2017 , ... FirstAlign ( http://www.firstalign.com ), combines strategies and ... (AI) thinking, announced today the launch of its revamped web presence. , ... offers a more comprehensive understanding of the organization’s business and machine learning solutions. ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... company specializing in medical device compliance and commercialization, has just released a ... activities. , FDA is more adamant than ever about medical device, pharmaceutical, ...
(Date:9/20/2017)... ... 2017 , ... Compliancy Group is proud to announce that ... helped another long-time client pass their Department of Health and Human Services (HHS) ... Thanks to the help of the Compliancy Group's Audit Response Program™, not a ...
Breaking Medicine News(10 mins):